Evercore ISI lowered the firm’s price target on Bausch + Lomb (BLCO) to $17 from $17.50 and keeps an In Line rating on the shares as part of the firm’s medical technology and life science tools Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb Sets Date for First-Quarter 2026 Results and Investor Call
- Bausch + Lomb’s ELIOS Glaucoma System Hits Key Efficacy Marks in 24‑Month U.S. Trial
- Bausch + Lomb announces 24-month U.S. data on ELIOS system in Glaucoma
- Bausch + Lomb Launches R&D Webinar Series Spotlighting Glaucoma Pipeline
- Trump Trade: L’Oreal, Bausch + Lomb sue for Trump tariff refunds